Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
May 21 2019, 8:30 AM EDT

Cellectar Biosciences Announces Closing of $10.0 Million Financing
May 20 2019, 4:10 PM EDT

Cellectar Biosciences Announces $10.0 Million Financing
May 16 2019, 8:52 AM EDT

Stock Overview

Symbol	CLRB
Exchange	Nasdaq
Market Cap	19.73m
Last Price	$2.10
52-Week	$1.22 - $12.76

05/24/2019 04:00 PM EDT

Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 646-915-3820
monique@lifesciadvisors.com

Management Team

James Caruso
President, CEO and Director

Jarrod Longcor
Chief Business Officer

Charles "Chip" Bernhardt
Interim Chief Financial Officer

Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.